Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

'As a woman you're just told to deal with these symptoms,' Lydia Southam says about her cancer diagnosis and struggle to be ...

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to discovering new methods for diagnosing the disease and potential therapies. The ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...

Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway for new treatments. High-grade serous carcinoma, the most common type of ...

In the field of gynecologic cancer, low-grade serous ovarian cancer (LGSOC) has been poorly understood and underinvestigated until recently. Similarly, understanding of the distinct properties and ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the treatment of adults with KRAS-mutated, recurrent low-grade serous ovarian ...